Cargando…

A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma

Purpose The therapeutic index of proteasome inhibitors may be improved through selective inhibition of a sub-component of the ubiquitin-proteasome system, such as the NEDD8-conjugation pathway. This multicenter, phase I, dose-escalation study assessed safety and the maximum tolerated dose (MTD), pha...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bhatia, Shailender, Pavlick, Anna C., Boasberg, Peter, Thompson, John A., Mulligan, George, Pickard, Michael D., Faessel, Hélène, Dezube, Bruce J., Hamid, Omid
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2016
Materias:	Phase I Studies
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4919369/ https://www.ncbi.nlm.nih.gov/pubmed/27056178 http://dx.doi.org/10.1007/s10637-016-0348-5

Ejemplares similares

The Nedd8‐activating enzyme inhibitor MLN4924 (TAK‐924/Pevonedistat) induces apoptosis via c‐Myc‐Noxa axis in head and neck squamous cell carcinoma
por: Zhang, Wenjuan, et al.
Publicado: (2018)

Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors
por: Lockhart, A Craig, et al.
Publicado: (2018)

Phase I study assessing the mass balance, pharmacokinetics, and excretion of [(14)C]-pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors
por: Zhou, Xiaofei, et al.
Publicado: (2020)

The use of the NEDD8 inhibitor MLN4924 (Pevonedistat) in a cyclotherapy approach to protect wild-type p53 cells from MLN4924 induced toxicity
por: Malhab, Lara J. Bou, et al.
Publicado: (2016)

Radiosensitization by the investigational NEDD8-activating enzyme inhibitor MLN4924 (pevonedistat) in hormone-resistant prostate cancer cells
por: Wang, Xiaofang, et al.
Publicado: (2016)

The NAE inhibitor pevonedistat (MLN4924) synergizes with TNF-α to activate apoptosis
por: Wolenski, F S, et al.
Publicado: (2015)

Pevonedistat (MLN4924): mechanism of cell death induction and therapeutic potential in colorectal cancer
por: Ferris, Jennifer, et al.
Publicado: (2020)

A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors
por: Adjei, Alex A., et al.
Publicado: (2016)

The NEDD8-activating enzyme inhibitor MLN4924 reduces ischemic brain injury in mice
por: Yu, Huilin, et al.
Publicado: (2022)

MLN4924 (Pevonedistat), a protein neddylation inhibitor, suppresses proliferation and migration of human clear cell renal cell carcinoma
por: Tong, Shuai, et al.
Publicado: (2017)

Phase I study of MLN8237—investigational Aurora A kinase inhibitor—in relapsed/refractory multiple myeloma, Non-Hodgkin lymphoma and chronic lymphocytic leukemia
por: Kelly, Kevin R., et al.
Publicado: (2013)

An Integrative Pan-Cancer Analysis Revealing MLN4924 (Pevonedistat) as a Potential Therapeutic Agent Targeting Skp2 in YAP-Driven Cancers
por: Lan, Chungen, et al.
Publicado: (2022)

Effects of the NEDD8-Activating Enzyme Inhibitor MLN4924 on Lytic Reactivation of Kaposi's Sarcoma-Associated Herpesvirus
por: Chang, Pey-Jium, et al.
Publicado: (2017)

Mutations in UBA3 Confer Resistance to the NEDD8-Activating Enzyme Inhibitor MLN4924 in Human Leukemic Cells
por: Xu, G. Wei, et al.
Publicado: (2014)

The Nedd8-activating enzyme inhibitor MLN4924 suppresses colon cancer cell growth via triggering autophagy
por: Lv, Yongzhu, et al.
Publicado: (2018)

Phase 1 dose-escalation, pharmacokinetic, and cerebrospinal fluid distribution study of TAK-285, an investigational inhibitor of EGFR and HER2
por: LoRusso, Patricia, et al.
Publicado: (2013)

A first-in-human, phase 1 study of the NEDD8 activating enzyme E1 inhibitor TAS4464 in patients with advanced solid tumors
por: Yamamoto, Noboru, et al.
Publicado: (2021)

The p21-Dependent Radiosensitization of Human Breast Cancer Cells by MLN4924, an Investigational Inhibitor of NEDD8 Activating Enzyme
por: Yang, Dong, et al.
Publicado: (2012)

Correction: Mutations in UBA3 Confer Resistance to the NEDD8-Activating Enzyme Inhibitor MLN4924 in Human Leukemic Cells
Publicado: (2014)

The NEDD8-activating enzyme inhibitor MLN4924 induces G2 arrest and apoptosis in T-cell acute lymphoblastic leukemia
por: Han, Kun, et al.
Publicado: (2016)

The NEDD8-activating enzyme inhibitor MLN4924 induces DNA damage in Ph+ leukemia and sensitizes for ABL kinase inhibitors
por: Bahjat, Mahnoush, et al.
Publicado: (2019)

Correction for Yu et al., The NEDD8-activating enzyme inhibitor MLN4924 reduces ischemic brain injury in mice
Publicado: (2022)

Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors
por: Shah, Manisha H., et al.
Publicado: (2016)

Broad and potent antiviral activity of the NAE inhibitor MLN4924
por: Le-Trilling, Vu Thuy Khanh, et al.
Publicado: (2016)

Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes
por: Swords, R T, et al.
Publicado: (2017)

The Absence of PTEN in Breast Cancer Is a Driver of MLN4924 Resistance
por: Du, Meng-ge, et al.
Publicado: (2021)

The NEDD8-activating enzyme inhibitor MLN4924 sensitizes a TNFR1(+) subgroup of multiple myeloma cells for TNF-induced cell death
por: El-Mesery, Mohamed, et al.
Publicado: (2019)

Inhibition of neddylation modification by MLN4924 sensitizes hepatocellular carcinoma cells to sorafenib
por: Yang, Zelong, et al.
Publicado: (2019)

Neddylation inhibitor MLN4924 suppresses cilia formation by modulating AKT1
por: Mao, Hongmei, et al.
Publicado: (2019)

Preclinical studies reveal MLN4924 is a promising new retinoblastoma therapy
por: Aubry, Arthur, et al.
Publicado: (2020)

Both BRCA1-wild type and -mutant triple-negative breast cancers show sensitivity to the NAE inhibitor MLN4924 which is enhanced upon MLN4924 and cisplatin combination treatment
por: Misra, Shrilekha, et al.
Publicado: (2020)

The Anti-Tumor Activity of the NEDD8 Inhibitor Pevonedistat in Neuroblastoma
por: Foster, Jennifer H., et al.
Publicado: (2021)

Neddylation inhibitor MLN4924 suppresses growth and migration of human gastric cancer cells
por: Lan, Huiyin, et al.
Publicado: (2016)

The novel protective role of P27 in MLN4924-treated gastric cancer cells
por: Zhang, Q, et al.
Publicado: (2015)

Inhibiting Neddylation with MLN4924 Suppresses Growth and Delays Multicellular Development in Dictyostelium discoideum
por: Huber, Robert J., et al.
Publicado: (2021)

The potential oncogenic and MLN4924-resistant effects of CSN5 on cervical cancer cells
por: Zhang, Huilin, et al.
Publicado: (2021)

MLN4924 inhibits cell proliferation by targeting the activated neddylation pathway in endometrial carcinoma
por: Liu, Huanrong, et al.
Publicado: (2021)

MLN4924 Promotes Self-Renewal of Limbal Stem Cells and Ocular Surface Restoration
por: Li, Qingjian, et al.
Publicado: (2023)

MLN4924 suppresses neddylation and induces cell cycle arrest, senescence, and apoptosis in human osteosarcoma
por: Zhang, Yi, et al.
Publicado: (2016)

Neddylation inhibitor MLN4924 sensitizes head and neck squamous carcinoma cells to (S)-10-hydroxycamptothecin
por: Gu, Shanshan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_hkt8l50qgj4jlel8qvli52okl6